Biocryst Pharmaceuticals Inc (BCRX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biocryst Pharmaceuticals Inc (BCRX)

BCRX 7.030

-1.8%

Nov 6 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	9/17/2007 8:28:55 PM
	of 269

08:23 am BioCryst Pharm: Caris & Company reiterates Above Average. Target $10 to $13. Caris is reiterating their Above Average rating and raising their tgt to $13.00 from $10.00 per share, based on their expectation that BCRX could report positive Phase II results from peramivir in influenza before the end of the year. Firm believes BCRX could potentially report positive results of Phase II trial NCT00419263 of peramivir administered intramuscularly before the end of the year.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next